Form 4: Arcutis EVP & CMO Sells Shares for Tax Obligations

Arcutis Biotherapeutics' Executive Vice President and Chief Medical Officer, Patrick Burnett, sold 4,188 shares of common stock in August 2025 to cover tax withholding obligations related to vested restricted stock units.

Summary

• Patrick Burnett, Executive Vice President and Chief Medical Officer of Arcutis Biotherapeutics, Inc., sold a total of 4,188 shares of common stock.
• The sales occurred on August 19, 2025, and August 21, 2025.
• On August 19, 2025, 1,750 shares were sold at a weighted average price of $16.1604 per share, with prices ranging from $15.87 to $16.73.
• On August 21, 2025, 2,438 shares were sold at a weighted average price of $15.5738 per share, with prices ranging from $15.43 to $15.65.
• These transactions were executed to cover tax withholding obligations associated with the vesting of performance-based Restricted Stock Units.
• The sales were conducted under a Rule 10b5-1 trading plan adopted on December 12, 2024, with a plan end date of February 27, 2026.
• Following these transactions, Patrick Burnett beneficially owns 104,811 shares of Arcutis Biotherapeutics common stock.

Sentiment

Score: 5

Explanation: The filing reports routine, pre-scheduled sales by an executive to cover tax obligations related to vested equity, which is a neutral event for the company's operational performance or strategic direction.

Positives

• Vesting of performance-based Restricted Stock Units indicates the achievement of company or individual performance targets.
• The sales were pre-planned under a Rule 10b5-1 trading plan, suggesting a non-discretionary, routine transaction.

Negatives

• An executive selling shares, even for tax purposes, reduces their direct ownership stake in the company.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: A minor reduction in executive ownership, but the reason (tax withholding) is routine and generally not a cause for concern. The existence of a 10b5-1 plan provides transparency.
• Employees: The vesting of performance-based RSUs could be seen as a positive indicator of company performance, potentially boosting morale.

Key Dates

Recommendation

This Form 4 filing details routine, pre-scheduled sales by an executive to cover tax obligations arising from vested equity. Such transactions are common and do not typically reflect a change in the executive's confidence in the company's long-term prospects or its operational performance. Therefore, this filing alone does not provide a basis for a change in investment recommendation; a "hold" stance is appropriate as it does not alter the fundamental investment thesis for Arcutis Biotherapeutics.

Keywords

Arcutis Biotherapeutics, ARQT, Patrick Burnett, SEC Form 4, Insider Trading, Stock Sale, Restricted Stock Units, RSU Vesting, Tax Withholding, 10b5-1 Plan, Biotechnology, Pharmaceuticals